GO
Loading...

Enter multiple symbols separated by commas

Stocks Sanofi SA

More

  • Sept 3- Genzyme Corp agreed to pay $32.59 million, admit wrongdoing and enter a deferred prosecution agreement to resolve U.S. criminal charges over its marketing of the surgical implant Seprafilm, the Department of Justice said on Thursday. Sanofi bought Genzyme in 2011.. According to papers filed with the federal court in Tampa, Florida, Genzyme admitted and...

  • Sept 3- Genzyme Corp agreed to pay $32.59 million, admit wrongdoing and enter a deferred prosecution agreement to resolve U.S. criminal charges over its marketing of the surgical implant Seprafilm, the Department of Justice said on Thursday. Sanofi bought Genzyme in 2011.. According to papers filed with the federal court in Tampa, Florida, Genzyme admitted and...

  • Insulin infusion device maker CeQur raises $100 mln Tuesday, 1 Sep 2015 | 6:53 AM ET

    LONDON, Sept 1- Privately held company CeQur, which is developing the world's first three-day insulin infusion device for people with type 2 diabetes, has raised $100 million in a funding round that shows strong investor appetite for hot medical technology. The patch-like insulin infusion device offers an alternative to daily insulin injections made by the...

  • Google, Sanofi team up to improve diabetes care Monday, 31 Aug 2015 | 10:26 AM ET

    Aug 31- Google Inc and French drugmaker Sanofi SA said they will partner to develop tools to improve the management and treatment of diabetes. Sanofi will work with Google's life sciences team to collect, analyze and understand information impacting diabetes, which is expected to affect 592 million by 2035, according to the International Diabetes...

  • NEW YORK— Shares of The Medicines Co. surged in premarket trading Monday after the company and its partner Alnylam Pharmaceuticals Inc. reported study results suggesting effectiveness for a potential cholesterol drug. Shares of Medicines jumped $5.98, or 17.8 percent, to $39.62 in premarket trading. Regeneron Pharmaceuticals Inc. and Sanofi sell...

  • Results with Alnylam Pharmaceuticals and Medicines Co's experimental product ALN-PCSsc highlight the competition for a market tipped to generate billions of dollars in sales. Amgen's Repatha and a rival product, Praluent, from Sanofi and Regeneron Pharmaceuticals, are each expected to generate more than $2 billion a year in sales by 2020, according to...

  • WASHINGTON, Aug 27- The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those at high risk of cardiovascular disease. Last month the FDA approved a similar drug from Regeneron Pharmaceuticals Inc and Sanofi SA. The drugs are expected to generate more than $2 billion a...

  • Amgen wins approval for second biotech cholesterol drug Thursday, 27 Aug 2015 | 5:18 PM ET

    WASHINGTON— Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that have been used for decades. Thousand Oaks, California- based Amgen priced the drug slightly below a similar drug Praluent, which costs $14,600 per year. Sanofi and partner...

  • Getting a flu shot? There are new options Wednesday, 26 Aug 2015 | 4:07 PM ET

    TRENTON, N.J.— People planning on getting a flu shot this season have several options to discuss with their doctors. Three vaccines may appeal to people squeamish about the inch-long needles typically used to give flu shots. Another option gives a high dosage for those needing extra protection.

  • AbbVie buys special review voucher for $350 mln Wednesday, 19 Aug 2015 | 10:41 AM ET

    Aug 19- AbbVie Inc has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs. United Therapeutics received a rare pediatric disease priority review voucher in March after its drug, Unituxin, was approved by the U.S. Food and Drug Administration to treat...

  • At what cost? Debate rages over cholesterol drugs Thursday, 6 Aug 2015 | 12:13 PM ET
    In this image provided by Sanofi and Regeneron Pharmaceuticals, shows packaging for the drug Praluent.

    Estimates of annual spending on PCSK9 drugs are as high as $150 billion, but drugmakers expect much lower.

  • Are we seeing a new dawn of innovation in pharma? Wednesday, 5 Aug 2015 | 1:50 AM ET
    Modernizing Medicine's electronic medical assistant.

    Innovation has always been the blood pumping through the body of the pharma industry, but in recent years the supply seemed to be getting poorer.

  • *Shares up 9.3 pct at $605.93. Aug 4- Regeneron Inc's blockbuster eye drug, Eylea, showed no signs of a slowdown as the drugmaker raised the full-year sales forecast for its flagship product above at least four analysts' expectation. The company's shares rose to a record of $605.93 in early trading on Tuesday.

  • Aug 4- Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit due to strong demand for its blockbuster eye drug, Eylea. Leerink Partners analysts expect the drug to hit peak annual sales of more than $5 billion. Regeneron's net income rose to $195 million, or $1.69 per share, in the second quarter ended June 30 from $96 million, or 85 cents...

  • Drugmaker Regeneron's revenue jumps on Eylea sales Tuesday, 4 Aug 2015 | 6:39 AM ET

    Aug 4- Regeneron Pharmaceuticals Inc reported a 50 percent rise in quarterly revenue, boosted by increasing demand for its blockbuster eye drug, Eylea. The company's net income nearly doubled to $195 million, or $1.69 per share, in the second quarter ended June 30, from $96 million, or 85 cents per share, a year earlier. The biotechnology company's revenue, including...

  • July 30- Amgen Inc on Thursday reported higher-than-expected second-quarter profit and revenue, helped by strong sales of its Enbrel rheumatoid arthritis drug and cost cutting, and the company raised its full-year forecasts. Excluding special items, Amgen earned $2.57 per share, topping analysts' average expectations by 14 cents, according to Thomson...

  • UPDATE 1-Sanofi's diabetes sales slow, Genzyme's jump Thursday, 30 Jul 2015 | 4:54 AM ET

    PARIS, July 30- Sanofi reported lower second quarter sales for its strategic diabetes division on Thursday, hurt by continued pricing pressure in the United States, but it's biotech arm Genzyme recorded another quarter of double-digit growth, enabling the French drugmaker to beat forecasts overall. Forced to agree to increased rebates to maintain market...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent, newly approved cholesterol drugs could "wreak financial havoc" among its clients. Express Scripts, which administers drug benefits for employers and health plans and also runs large mail-order pharmacies, has been challenging...

  • July 29- Express Scripts Holding Co, the largest pharmacy benefit manager in the United States, on Wednesday said the cost of potent new cholesterol drugs called PCSK9 inhibitors could "wreak financial havoc" among its clients. U.S. regulators on Friday approved the first of the new medicines, Praluent from Regeneron Pharmaceuticals Inc and Sanofi SA.

  • AZN sells off non-core drugs Monday, 27 Jul 2015 | 10:00 AM ET
    AZN sells off non-core drugs

    AstraZeneca sells off another medication to bring revenue.